FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Miquel Aranda

Research Profile

Disorders

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda
How much fat loss is needed for lipoatrophy to become clinically evident?
Josep Mallolas; Daniel Podzamczer; Ana Milinkovic; Pere Domingo; Bonaventura Clotet; Esteve Ribera; Félix Gutiérrez; Hernando Knobel; Jaime Cosin; Elena Ferrer; José Alberto Arranz; Victor Roca; Francesc Vidal; Javier Murillas; Judit Pich; Enric Pedrol; Josep M Llibre; David Dalmau; Isabel García; Miquel Aranda; Ana Cruceta; Esteban Martínez; José L Blanco; Elisa de Lazzari; José M Gatell
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montserrat Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-Lacasa; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; José Pedreira; Ana Lérida; Rafael Rubio; Luis del Río
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Miquel Aranda (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda
How much fat loss is needed for lipoatrophy to become clinically evident?
AIDS research and human retroviruses 2009;25(6):563-7.
2009: Josep Mallolas; Daniel Podzamczer; Ana Milinkovic; Pere Domingo; Bonaventura Clotet; Esteve Ribera; Félix Gutiérrez; Hernando Knobel; Jaime Cosin; Elena Ferrer; José Alberto Arranz; Victor Roca; Francesc Vidal; Javier Murillas; Judit Pich; Enric Pedrol; Josep M Llibre; David Dalmau; Isabel García; Miquel Aranda; Ana Cruceta; Esteban Martínez; José L Blanco; Elisa de Lazzari; José M Gatell
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):29-36.
2007: Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montserrat Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-Lacasa; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; José Pedreira; Ana Lérida; Rafael Rubio; Luis del Río
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Journal of acquired immune deficiency syndromes (1999) 2007;44(2):139-47.
2004: Alfonso Casado; Xavier Badia; Ezequiel Consiglio; Elena Ferrer; Alicia González; Enric Pedrol; José M Gatell; C Azuaje; Josep M Llibre; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; Daniel Podzamczer
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
HIV clinical trials 2004;5(3):132-9.
2003: Esteban Martínez; Juan A Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; Melcior Riera; Enric Pedrol; Lluís Force; Josep M Llibre; Ferran Segura; Cristóbal Richart; Cristina Cortés; Manuel Javaloyas; Miquel Aranda; Anna Cruceta; Elisa De Lazzari; José M Gatell
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
The New England journal of medicine 2003;349(11):1036-46.
2002: Daniel Podzamczer; Elena Ferrer; Ezequiel Consiglio; José M Gatell; Pepa Perez; José Luis Perez; Elena Luna; Alicia González; Enric Pedrol; Luisa Lozano; Imma Ocaña; Josep M Llibre; Arnaldo Casiró; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; José M Miró; Xavier Badía; Alfonso Casado; Sergio Lupo; Pedro Cahn; Manel Maños; Jordi Estela
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Antiviral therapy 2002;7(2):81-90.
2000: Felipe García; Hernando Knobel; Maria Antonia Sambeat; Julio Arrizabalaga; Miquel Aranda; Joan Romeu; David Dalmau; Ferran Segura; JL Gomez-Sirvent; Elena Ferrer; Anna Cruceta; Teresa Gallart; Tomás Pumarola; José M Miró; José M Gatell
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
AIDS (London, England) 2000;14(16):2485-94.